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Allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia -
Current concepts and Brazilian experience
Transplante de célula-tronco hematopoética na leucemia mielóide crônica - Conceitos atuais e
experiência brasileira
Cármino A. de Souza1 Allogeneic Stem Cell Transplantation (ASCT) remains the unique curative therapy for
CML in all clinical phases of the disease. However, the results of Imatinib Mesilate
(IM) therapy are sufficiently impressive to have displaced ASCT to second- or third-
line treatment depending on the availability of newly developed tyrosine kinase
inhibitors. The decision for transplantation depends on a variety of clinical and
biological situations. The Leukemia Net recommendations as well the NCCN guidelines
help us to choose the best moment to perform ASCT. In 1998, Gratwohl and colleagues
published a score in order to establish the risk of ASCT before the procedure. In
2005, the Brazilian group, studying more than 1000 patients in an independent
population, validated the risk score previously proposed by the EBMT Group. In this
paper we discuss the position of ASCT in a country such as Brazil that presents
resource limitations. In 2006, the EBMT published an activity survey about ASCT in
CML and discussed the changes in treatment indications over the past 15 years and
presented differences in medical conduct in West versus East Europe concerning
ASCT indication. Despite of risks, ASCT remains a valid curative treatment. To delay
or to perform the ASCT in advanced phases (accelerated- or blastic-phase) increases
procedure-related mortality rates and reduces the probability of cure. Rev. bras.
hematol. hemoter. 2008; 30(Supl. 2):30-32.
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The approach of primary treatment for newly diagnosed
CML patients has been changed due to the effectiveness
and safety of imatinib mesylate (IM).1-6 This drug has shown
activity in all disease phases but the best responses are seen
in the early chronic phase.7-11 However, 20%-30% of newly
diagnosed patients using 400 mg per day of imatinib fail to
achieve a good molecular response11 and a small proportion
has undetectable levels of BCR-ABL transcripts.12 BCR-ABL
positive hematopoietic progenitors persist in the marrow of
patients in CCR, indicating that the malignant progenitor may
be suppressed but probably not eliminated in the course of
imatinib treatment.13 Besides these considerations, concerns
exist regarding the development of resistance to imatinib.14-18
Allogeneic hematopoietic stem cell transplantation
(HSCT) results in long-term disease control and may cure
selected patients with CML, depending on the contribution
of the graft-versus-leukemia effect.19-21 Comparisons of
survival rates among treatments are used to formulate gene-
ral treatment policies but the decision to offer or not an
allogeneic HSCT should be based on the probability of
success using this procedure. Prognostic scores
incorporating patient – and disease – specific variables can
assist decision-making.22 The European Blood and Marrow
Transplant Group (EBMT) devised a prognostic score for
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patients receiving allogeneic HSCT.23 In the IM era and in
situations with limited resources we need information
regarding the best chance to benefit from HSCT.
More and more data have been published in recent
years regarding the use of IM as front line therapy for CML
as well the newly developed TK inhibitor as Nilotinib and
Dasatinib. The high level of hematological and cytogenetics
responses associated to safety of the drugs created a new
and important paradigm in the treatment of CML. However,
the possibility of progression, are the most important
concerns to be analyzed in order to choose the most effective
and less toxic approach. Allogeneic HSCT has demonstrated
to be able to cure CML in all clinical phases. However, the
risks of high morbidity and TRM associated with acute and
chronic GVHD must be considered against the benefit of
HSCT. The present challenge is to identify subsets of patients
to receive either TK inhibitors or HSCT. Based on our
observation and in important papers published by Gratwohl23
and then by Passweg,22 patients presenting low risk scores
(0 to 2) proposed by the EBMT, may be the best subgroup to
be treated with HSCT. In contrast, patients treated with HSCT
and presenting risk score 3 or beyond, showed low OS and
DFS and high TRM and relapse rate. In addition, the status
of disease had showed a high power to predict outcome.
Patients in accelerated phase or in blast crisis had had a very
bad prognosis. Although HSCT might be the unique treatment
able to cure patients in advanced phase, only a few numbers
of patients in this group may achieve a long and stable
remission or definitive cure. Currently, two important points
should be balance: 1– to estimate the increase in risk if IM is
given first and transplants are performed only at progression
or IM failure, and 2 – a definition of a patient cohort with
such low chances of success with HSCT that it is not
justifiable to use the limited resources.
The Brazilian paper report previously24 had the aim to
present the results of CML patient in developing country
treated with HSCT, and tried to validate the EBMT risk score.
The patients in the study represent the evolution and the
history of 20 years of HSCT in CML in Brazil. Our data, in an
independent population, get to demonstrate that the EBMT
risk score is reliable, and represents a useful guide for clinical
decision making. Our data present slight differences
compared with the original Gratwohl study.23 Disease status
and recipient male/donor female presented the worst
prognostic impact factors, whereas patients' age and time
from diagnosis to transplant were not significant either in
univariate or in multivariate analysis. These differences can
be related to differences in patients' characteristics between
the two populations: we had fewer patients in blast crisis
compared to the original study (4% vs. 14%), our patients
were much younger, as assessed by the proportion of patients
younger than 20 years (14% on our study vs. 8% in the origi-
nal study), and the time from diagnosis to transplantation
was much longer (79% of our patients >12 months from
diagnosis to transplantation, compared to 51% in the study
by Gratwohl et al). Regarding the time from diagnosis to
transplant, we speculate that in our country there is a delay
in making the diagnosis and referring to a bone marrow
transplant center. Concerning the results of OS and TRM
according to periods of time they showed a progressive
improvement which could be predictable with the improving
of the support treatment, modern typing, GVHD and CMV
control. EBMT activity survey published in 2004 showed the
changes in disease indication over the past 15 years.25 This
paper demonstrated a dramatically reduction of HSCT in the
west Europe. However, in the east Europe the number of
transplants increased in the same period. HSCT remains as
an important alternative and countries presenting reduced
resources may consider this procedure in an early phase of
disease using patient' and transplant' risks. The EBMT score
remains as an important instrument to decision making.
Despite these slight differences, the Brazilian study validates
the EBMT risk score23 and confirms its usefulness for point-
decision in a development country, especially in choosing
the best treatment in the IM era.
Resumo
O transplante alogênico de célula-tronco hematopoética permane-
ce como a única terapêutica com potencial terapêutico para a LMC
in todas as fases da doença. Entretanto, os resultados com a utiliza-
ção do mesilato de imatinibe são suficientemente impressionantes
para deslocar a utilização do transplante para segunda ou mesmo
terceira linha de tratamento dependendo da disponibilidade dos
novos inibidores de tirosino quinases. A decisão para a indicação
do transplante depende da fase clínica e dos achados biológicos. As
recomendações da Leukemia Net e as diretrizes da NCCN nos
auxiliam a escolher o melhor momento para a elaboração do trans-
plante. Em 1998, Gratwohl e colaboradores publicaram um escore
no sentido de estabelecer o risco do transplante antes de sua reali-
zação. Em 2005, um grupo brasileiro estudando mais de 1.000
pacientes em uma população independente validou o escore de ris-
co proposto pelo grupo europeu. Neste manuscrito o autor discuti-
rá a posição do transplante em países com limitações de recursos
como o Brasil. Em 2006, a mesma escola européia publicou um
estudo de monitoramento do transplante e discutiu as mudanças
desta modalidade de tratamento nos últimos 15 anos e apresentou
as diferenças no comportamento médico na Europa do oeste (mais
rica) versus do leste (mais pobre) na indicação e utilização do
transplante. A despeito dos riscos, o transplante permanece como
uma terapêutica curativa válida. Atrasar a indicação ou realizar o
procedimento em fases avançadas, como a fase acelerada ou blástica,
aumenta o risco de mortalidade relacionada ao procedimento e
reduz a probabilidade de cura. Rev. bras. hematol. hemoter. 2008;
30(Supl. 2):30-32.
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